JMT Cochrane, Board member Wellcome and Glaxo; Director of Commercial Affairs for Europe
- Date:
- 17 Aug 2001
- Reference:
- WF/M/AV/O/02/35
- Part of:
- Wellcome Foundation Ltd
- Archives and manuscripts
Collection contents
About this work
Description
The interview comprises a close assessment of the company, of its relationship with WT, the flotation and the merger with Glaxo. Other topics discussed include:
* biography
* differences between UK and US company
* reasons for flotation and preparations for sale of second lot of shares
* the effects of public accountability on the company, budgeting
* AJ Shepperd as chairman
* restructuring of the business, focus of research, commercial interests
* Semprex
* principles behind marketing drugs, establishing where markets are available, pricing
* salaries and staffing
* research: David Barry and Trevor Jones; relationship between UK and USA research functions
* management of research and product development: Zantac [Glaxo product]
* Wellbutrin
* strategic review of company
* markets in Germany and Japan
* relationship between company and WT
* Glaxo's approach to WT and reasons for wishin to takeover WF; process of selecting staff post-merger
* summary of Glaxo
* WF as an employeer/staff morale and attitudes
* John Robb, management and leadership style
Publication/Creation
Physical description
Terms of use
Where to find it
Location Status Access Closed storesWF/M/AV/O/02/35:Box 3